Image of Jessica Delbaum

Jessica Delbaum

Partner

Jessica focuses on defending multi-national companies’ mergers and acquisitions before the Federal Trade Commission and the Department of Justice as well as coordinating the multi-jurisdictional antitrust defense of transactions. She also counsels clients on an extensive array of antitrust issues such as competitor collaborations, cartel leniency applications and Hart-Scott-Rodino Act compliance, including integration planning.

Jessica has also defended substantive merger investigations involving a wide variety of industries, including agriculture, pharmaceuticals, medical devices, biotechnology, media, aviation, technology, chemicals and finance.

After graduating from law school, Jessica was an Attorney General’s Honors Program Attorney in the Antitrust Division of the Department of Justice. While at the Division, she investigated possible violations of the antitrust laws involving mergers and acquisitions, the reporting and waiting requirements of the Hart-Scott-Rodino Act and civil price-fixing.

Jessica is a Chambers-ranked practitioner, and her practice has also been recognized by various other publications including Legal 500. In 2021, Jessica was named to The BTI Consulting Group’s Client All-Stars List, a rare client-designated honor for excellence in client service as reflected in a survey of corporate America’s top decision makers.

Jessica is a regular speaker on a variety of antitrust-related topics.

Experience

Representative matters

JetBlue Airways on its proposed acquisition of Spirit Airlines and in its Northeast Alliance with American Airlines.

Paramount in its sale of Simon & Schuster to KKR (as well as its proposed sale to Penguin Random House) and in its sale of C|NET to Red Ventures.

Dover Corporation in its acquisition of FW Murphy Production Controls and in its acquisition of Belanger, Inc.

invoX Pharma, a wholly owned subsidiary of Sino Biopharmaceutical Limited, in connection with its tender offer for F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company.

Published Work

  • Delbaum, Jessica, Co-author. (2022) Mergers & Acquisitions in Antitrust Adviser (6th ed.)
  • Delbaum, Jessica, Co-author. (2014, 2020, 2022) “Merger Remedies in the US: An Overview of the Leading Cases,” Concurrences
  • Delbaum, Jessica, Co-author. (2020) Merger Remedies, United States, Global Competition Review
  • Delbaum, Jessica, Co-author. (2020) “Edgewell/Harry’s: When a Maverick is More Than Its Market Share,” The M&A Lawyer

Speaking Engagements

  • Jessica is a regular speaker on a variety of antitrust-related topics.

Leadership Positions And Professional Affiliations

  • Member, American Bar Association Antitrust Law Section
  • Member, Executive Committee, New York State Bar Association Antitrust Law Section
Recognition
Jessica is a pleasure to work with. She is very responsive, knowledgeable and also very commercial.
Chambers USA, 2023
She has an incredible mind, she’s very helpful and very pragmatic. She’s fantastic.
Chambers USA, 2022

Awards

  • Ranked by Legal 500 and Chambers USA
  • Recognized in the BTI Consulting Group’s Client All-Stars List
  • Featured in Who’s Who Legal Competition List
  • Recognized as a New York “Super Lawyer” for antitrust

Qualifications

Admissions

New York

Courts

United States Supreme Court
United States District Court for the Eastern District of New York
United States District Court for the Southern District of New York

Academic

B.A. (Economics-Philosophy), magna cum laude, Columbia College
J.D., cum laude, Harvard University
Articles Editor, International Law Journal
Disclaimer
A&O Shearman was formed on May 1, 2024 by the combination of Shearman & Sterling LLP and Allen & Overy LLP and their respective affiliates (the legacy firms). Any matters referred to above may include matters undertaken by one or more of the legacy firms rather than A&O Shearman.